NRP1 and gastric adenocarcinoma: The upregulation of YTHDF1, CD160, TNFRSF25, CTLA4, TNFRSF14, JAK2, and CD244 and knockdown of TNFSF4, NRP1, CD276, and CD244 could be viable targets in STAD.